CBFB and acute myeloid leukemia: We compared mRNA- and gDNA-based approaches in 23 patients with PML::RARA-/RUNX1::RUNX1T1-/CBFB::MYH11-positive AML and demonstrated, that mRNA approach may underestimate or (less frequently) overestimate MRD level [11].